A new review in Genes & Diseases highlights FTO, an enzyme involved in RNA modification, as a potentially important biomarker and therapeutic target across gastrointestinal cancers. The article brings together current understanding of FTO in gastric, liver, colorectal and pancreatic cancers, revealing a complex role in which the enzyme can both promote and suppress cancer progression depending on biological context.

FTO is an RNA demethylase capable of removing chemical modifications including N6-methyladenosine (m6A). Through this activity, FTO can influence RNA stability, translation, degradation and movement within cells. These processes can ultimately affect how cancer cells grow, spread, respond to their environment and withstand treatment.

Across gastrointestinal cancers, FTO is associated with pathways controlling tumour growth, metastasis, metabolic reprogramming, immune escape, ferroptosis and treatment resistance. Importantly, its effects are not uniform. FTO can function as an oncogenic factor in some circumstances while suppressing tumour progression in others. This dual role indicates that targeting FTO will require careful consideration of the molecular and cancer-specific context.

The review also highlights the extensive mechanisms that regulate FTO. Transcription factors, RNA-related regulators and epigenetic mechanisms can influence FTO expression, while post-translational modifications including acetylation, ubiquitination, SUMOylation and phosphorylation can affect its stability, cellular location, degradation and activity. Understanding these regulatory networks may reveal additional ways to control FTO more precisely.

A growing range of small-molecule FTO inhibitors further supports interest in the enzyme as a potential drug target. Compounds including Rhein, FB23-2, CS1/CS2, Dac51 and 18097 have demonstrated anticancer potential in experimental settings. Some FTO-targeting approaches may also complement immunotherapy, raising the possibility of future combination treatment strategies. However, clinical validation is still required, particularly for gastrointestinal cancers.
# # # # # #
Genes & Diseases publishes rigorously peer-reviewed and high quality original articles and authoritative reviews that focus on the molecular bases of human diseases. Emphasis is placed on hypothesis-driven, mechanistic studies relevant to pathogenesis and/or experimental therapeutics of human diseases. The journal has worldwide authorship, and a broad scope in basic and translational biomedical research of molecular biology, molecular genetics, and cell biology, including but not limited to cell proliferation and apoptosis, signal transduction, stem cell biology, developmental biology, gene regulation and epigenetics, cancer biology, immunity and infection, neuroscience, disease-specific animal models, gene and cell-based therapies, and regenerative medicine.
Scopus CiteScore: 10.4 |Impact Factor:14.6
# # # # # #
More information: https://www.keaipublishing.com/en/journals/genes-and-diseases/
Editorial Board: https://www.keaipublishing.com/en/journals/genes-and-diseases/editorial-board/
All issues and articles in press are available online in ScienceDirect (https://www.sciencedirect.com/journal/genes-and-diseases).
Submissions to Genes & Diseases may be made using Editorial Manager (https://www.editorialmanager.com/gendis/default.aspx).
Print ISSN: 2352-4820
eISSN: 2352-3042
CN: 50-1221/R
Contact Us: editor@genesndiseases.cn
X (formerly twitter): @GenesNDiseases (https://x.com/GenesNDiseases)
# # # # # #
Reference
Xinxin Zhang, Yufeng Han, Huimin Yin, Zhenjian Zhuo, Jing He, The role, regulatory mechanisms, and therapeutic implications of FTO in gastrointestinal cancer, Genes & Diseases, Volume 13, Issue 6, 2026,
102122, https://doi.org/10.1016/j.gendis.2026.102122

Funding
National Natural Science Foundation of China 32300473
National Natural Science Foundation of China 82002636
National Natural Science Foundation of China 82173593
Guangdong Basic and Applied Basic Research Foundation (China) 2023A1515220053
Science, Technology and Innovation Commission of Shenzhen, China JCYJ20220531093213030